1887

Journal of Medical Microbiology logo

Volume 70, Issue 7

8-hydroxyquinoline-5-(N-4-chlorophenyl) sulfonamide and fluconazole combination as a preventive strategy for biofilm in haemodialysis devices No Access

Abstract

The presence of biofilms in medical devices is a concerning and important clinical issue for haemodialysis patients who require constant use of prosthetic fistulae and catheters.

This prolonged use increases the risk of candidaemia due to biofilm formation. PH151 and clioquinol are 8-hydroxyquinoline derivatives that have been studied by our group and showed interesting anti- activity.

This study evaluated the biofilm formation capacity of species on polytetrafluoroethylene (PTFE) and polyurethane (PUR) and investigated the synergistic effects between the compounds PH151 and clioquinol and fluconazole, amphotericin B and caspofungin against biofilm cells removed from those materials. Further, the synergistic combination was evaluated in terms of preventing biofilm formation on PTFE and PUR discs.

Susceptibility testing was performed for planktonic and biofilm cells using the broth microdilution method. The checkerboard method and the time–kill assay were used to evaluate the interactions between antifungal agents. Antibiofilm activity on PTFE and PUR materials was assessed to quantify the prevention of biofilm formation.

, and showed ability to form biofilms on both materials. By contrast, did not demonstrate this ability. Synergistic interaction was observed when PH151 was combined with fluconazole in 77.8 % of isolates and this treatment was shown to be concentration- and time-dependent. On the other hand, indifferent interactions were predominantly observed with the other combinations. A reduction in biofilm formation on PUR material of more than 50 % was observed when using PH151 combined with fluconazole.

PH151 demonstrated potential as a local treatment for use in a combination therapy approach against biofilm formation on haemodialysis devices.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): biofilm , Candida , haemodialysis , polytetrafluoroethylene and polyurethane
Funding
This study was supported by the:
  • FAPERGS (Award 16/2551-0000517-6)
    • Principle Award Recipient: AlexandreMeneghello Fuentefria
© 2021 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001377
2021-07-14
2024-04-20
Loading full text...

Full text loading...

References

  1. Agarwal AK, Haddad NJ, Vachharajani TJ, Asif A, Archil B et al. Innovations in vascular access for hemodialysis. Kidney Int 2019; 95:1053–1063 [View Article]
     [Google Scholar]
  2. Murea M, Geary RL, Davis RP, Moossavi S et al. Vascular access for hemodialysis: A perpetual challenge. Semin Dial 2019; 32:527–534 [View Article]
     [Google Scholar]
  3. Buggs J, Tanious A, Camba V, Albertson C, Rogers E et al. Effective arteriovenous fistula alternative for hemodialysis access. Am J Surg 2018; 216:1144–1147 [View Article]
     [Google Scholar]
  4. Jadlowiec CC, Mannion EM, Lavallee M, Brown MG et al. Hemodialysis access in the elderly: Outcomes among patients older than seventy. Ann Vasc Surg 2016; 31:77–84 [View Article]
     [Google Scholar]
  5. Allon M. Vascular access for hemodialysis patients: New data should guide decision making. Clin J Am Soc Nephrol 2019; 14:954–961 [View Article]
     [Google Scholar]
  6. Allon M, Brouwer-Maier DJ, Abreo K, Baskin KM, Bregel K et al. Recommended clinical trial end points for dialysis catheters. Clin J Am Soc Nephrol 2018; 13:495–500 [View Article]
     [Google Scholar]
  7. Andreotti R, Paula A, Ourives J et al. Hemodialysis with extended central venous catheter use. Rev Iberoam Micol 2016; 33:2–5 [View Article]
     [Google Scholar]
  8. Kaur H, Chakrabarti A. Strategies to reduce mortality in adult and neonatal candidemia in developing countries. J Fungi 2017; 3: [View Article]
     [Google Scholar]
  9. Mirzaei R, Mohammadzadeh R, Alikhani MY, Shokri Moghadam M, Karampoor S et al. The biofilm-associated bacterial infections unrelated to indwelling devices. IUBMB Life 2020; 72:1271–1285 [View Article]
     [Google Scholar]
  10. Rupp ME, Karnatak R. Intravascular catheter–related bloodstream infections. Infect Dis Clin North Am 2018; 32:765–787 [View Article]
     [Google Scholar]
  11. Galocha M, Pais P, Cavalheiro M, Pereira D, Viana R et al. Divergent approaches to virulence in C. Albicans and C. Glabrata: Two sides of the same coin. Int J Mol Sci 2019; 20: [View Article]
     [Google Scholar]
  12. Epelbaum O, Chasan R. Candidemia in the Intensive Care Unit. Clin Chest Med 2017; 38:493–509 [View Article]
     [Google Scholar]
  13. Wan Ismail WNA, Jasmi N, Khan TM, Hong YH, Neoh CF. The economic burden of Candidemia and invasive candidiasis: A systematic review. Value Heal Reg Issues 2020; 21:53–58 [View Article]
     [Google Scholar]
  14. Nett JE, Andes DR. Contributions of the biofilm matrix to candida pathogenesis. J Fungi 2020; 6:33–38 [View Article]
     [Google Scholar]
  15. Li W-S, Chen Y-C, Kuo S-F, Chen F-J, Lee C-H. The impact of biofilm formation on the persistence of candidemia. Front Microbiol 2018; 9:1–10
     [Google Scholar]
  16. Íñigo M. Practical approach by type of pathogens fungal biofilms: From bench to bedside. Rev Esp Quimioter 2018; 31:35–38
     [Google Scholar]
  17. Dimondi P, Townsend ML, Johnson M, Durkin M. Antifungal catheter lock therapy for the management of a persistent Candida albicans bloodstream infection in an adult receiving hemodialysis. Pharmacotherapy 2014; 34:e120–e127 [View Article]
     [Google Scholar]
  18. Ben-Ami R. Treatment of invasive candidiasis: A narrative review. J Fungi 2018; 4: [View Article]
     [Google Scholar]
  19. de Oliveira Santos GC, Vasconcelos CC, Lopes AJO, de Sousa Cartágenes M do S, Filho AKDB et al. Candida infections and therapeutic strategies: Mechanisms of action for traditional and alternative agents. Front Microbiol 2018; 9:1351 [View Article]
     [Google Scholar]
  20. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19. Int J Antimicrob Agents 2020; 55:105938 [View Article]
     [Google Scholar]
  21. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr Clin Res Rev 2020; 14:241–246 [View Article]
     [Google Scholar]
  22. Kumar P. A review on quinoline derivatives as anti – methicillin resistant Staphylococcus aureus (MRSA) agents. BMC Chem 20201–14 [View Article]
     [Google Scholar]
  23. Touret F, de Lamballerie X. Of Chloroquine and covid-19. Antiviral Res 2020; 177:104762 [View Article]
     [Google Scholar]
  24. Perez DR, Sklar LA, Chigaev A. Pharmacology & therapeutics clioquinol: to harm or heal. Pharmacol Ther 2019; 199:155–163 [View Article]
     [Google Scholar]
  25. Sampson EL, Jenagaratnam L, Mcshane R. Metal protein attenuating compounds for the treatment of Alzheimer’s dementia. Cochrane Database Syst Rev 2014 [View Article]
     [Google Scholar]
  26. Cherdtrakulkiat R, Boonpangrak S, Sinthupoom N, Prachayasittikul S, Ruchirawat S et al. derivatives (halogen, nitro and amino) of 8-hydroxyquinoline with highly potent antimicrobial and antioxidant activities. Biochem Biophys Rep 2016; 6:135–141 [View Article]
     [Google Scholar]
  27. Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V. 8-Hydroxyquinolines: A review of their metal chelating properties and medicinal applications. Drug Des Devel Ther 2013; 7:1157–1178 [View Article]
     [Google Scholar]
  28. Singh YP, Pandey A, Vishwakarma S, Modi G. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer’s and Parkinson’s diseases. Mol Divers 2019; 23:509–526 [View Article]
     [Google Scholar]
  29. Pippi B, Reginatto P, Da Rosa Monte MG, Bergamo VZ, Dalla Lana DF et al. Evaluation of 8-hydroxyquinoline derivatives as hits for antifungal drug design. Med Mycol Med Mycol 2017; 55:763–773 [View Article]
     [Google Scholar]
  30. Pippi B, Machado G da RM, Bergamo VZ, Alves RJ, Andrade SF et al. Clioquinol is a promising preventive morphological switching compound in the treatment of Candida infections linked to the use of intrauterine devices. J Med Microbiol 2018; 67:1655–1663 [View Article]
     [Google Scholar]
  31. Joaquim AR, Pippi B, de Cesare MA, Rocha DA, Boff RT et al. Rapid tools to gain insights into the interaction dynamics of new 8-hydroxyquinolines with few fungal lines. Chem Biol Drug Des 2019; 93:1186–1196 [View Article]
     [Google Scholar]
  32. M27-A3 Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard-Third Edition. 2008
     [Google Scholar]
  33. Johnson MD, MacDougall C, Ostrosky-Zeichner L et al. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48:693–715 [View Article] [PubMed]
     [Google Scholar]
  34. Odds FC. Editorial synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52:1 [View Article] [PubMed]
     [Google Scholar]
  35. Camins BC. Prevention and treatment of hemodialysis-related bloodstream infections. Semin Dial 2013; 26:476–481 [View Article]
     [Google Scholar]
  36. Cavalheiro M, Teixeira MC. Candida biofilms: threats, challenges, and promising strategies. Front Med 2018; 5:1–15 [View Article]
     [Google Scholar]
  37. Silva S, Rodrigues CF, Araújo D, Rodrigues ME, Henriques M. Candida species biofilms’ antifungal resistance. J Fungi 2017; 3: [View Article]
     [Google Scholar]
  38. Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 2017; 45:737–779 [View Article]
     [Google Scholar]
  39. Bhattacharya S, Sae-Tia S, Fries BC. Candidiasis and mechanisms of antifungal resistance. Antibiotics (Basel) 2020; 9:312 [View Article]
     [Google Scholar]
  40. da Costa B, Pippi B, Andrzejewski Kaminski TF, Andrade SF, Fuentefria AM et al. In vitro antidermatophytic synergism of double and triple combination of clioquinol with CICLOPIROX and terBinafine. Mycoses 2020; 63:993–1001 [View Article]
     [Google Scholar]
  41. Morschhäuser J. The development of fluconazole resistance in candida albicans – an example of microevolution of a fungal pathogen. J Microbiol 2016; 54: [View Article]
     [Google Scholar]
  42. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ et al. Invasive candidiasis. Nat Rev Dis Primers 2018; 4:1–20 [View Article]
     [Google Scholar]
  43. Bersani I, Piersigilli F, Goffredo BM, Santisi A, Cairoli S et al. Antifungal drugs for invasive Candida infections (ICI) in neonates: Future perspectives. Front Pediatr 2019; 7:375 [View Article]
     [Google Scholar]
  44. Pippi B, Lopes W, Reginatto P, Silva FÉK, Joaquim AR et al. New insights into the mechanism of antifungal action of 8-hydroxyquinolines. Saudi Pharm J 2019; 27:41–48 [View Article]
     [Google Scholar]
  45. Pippi B, Joaquim AR, Lopes W, Machado GRM, Bergamo VZ et al. 8-hydroxyquinoline-5-sulfonamides are promising antifungal candidates for the topical treatment of dermatomycosis. J Appl Microbiol 2020; 128:1038–1049 [View Article]
     [Google Scholar]
  46. Khan MSA, Ahmad I. Antibiofilm activity of certain phytocompounds and their synergy with fluconazole against Candida albicans biofilms. J Antimicrob Chemother 2012; 67:618–621 [View Article]
     [Google Scholar]
  47. Gao Y, Zhang C, Lu C, Liu P, Li Y et al. Synergistic effect of doxycycline and fluconazole against Candida albicans biofilms and the impact of calcium channel blockers. FEMS Yeast Res 2013; 13:453–462 [View Article]
     [Google Scholar]
  48. Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother 2008; 62:153–155 [View Article]
     [Google Scholar]
  49. Janum S, Afshari A. Extracción del CATETER VENOSO Central en Pacientes Con Candidemia. Cochrane Database Syst Rev 2016
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001377
Loading
8-hydroxyquinoline-5-(N-4-chlorophenyl) sulfonamide and fluconazole combination as a preventive strategy for Candida biofilm in haemodialysis devices
J. Med. Microbiol. 70, 001377 (2021); https://doi.org/10.1099/jmm.0.001377
/content/journal/jmm/10.1099/jmm.0.001377
/content/journal/jmm/10.1099/jmm.0.001377
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error